Prolia - Publications and Expert Opinions | Amgen

SUMMARY OF PRODUCT CHARACTERISTICS

CONFERENCE REPORTS

Reports for download:
PDF
ASBMR Abstract Spotlight 2019
PDF
ESCEO Congress 2019
PDF
ESCEO Congress 2018
PDF
FFN Congress 2018
PDF
ECTS Congress 2018
PDF
ASBMR Abstract Spotlight 2018

UPCOMING CONGRESSES

icon-congress

(Virtual congress) WCO-IOF-ESCEO 2020

20–22 August 2020

icon-congress

(Virtual congress) ASBMR 2020

11–15 September 2020

icon-congress

(Digital congress) ECTS 2020

22–24 October 2020

EXPERT VIEWS

External expert videos

Prolia-Power-of-10-Video-1

Prolia® Power of 10 – Video 1

Recent advances in osteoporosis treatment

Prolia-Power-of-10-Video-2

Prolia® Power of 10 – Video 2

FREEDOM trial and extension

Prolia-Power-of-10-Video-3

Prolia® Power of 10 – Video 3

Convenience of treatment with Prolia®

ESCEO 2018: Prof. Eugene McCloskey

ESCEO 2018: Prof. Eugene McCloskey

Improving persistence in patients

ESCEO 2018: Prof. Eugene McCloskey

ESCEO 2018: Prof. Eugene McCloskey

Main benefit of long-term Prolia®

ESCEO 2018: Prof. Eugene McCloskey

ESCEO 2018: Prof. Eugene McCloskey

Discontinuing osteoporosis treatments

ESCEO 2018: Prof. Eugene McCloskey

ESCEO 2018: Prof. Eugene McCloskey

Re-assessing patients

ESCEO 2018: Prof. Eugene McCloskey

ESCEO 2018: Prof. Eugene McCloskey

Patient preference in osteoporosis treatments

ESCEO 2018: Prof. Eugene McCloskey

ESCEO 2018: Prof. Eugene McCloskey

Identifying patients suitable for Prolia®

ESCEO 2018: Prof. Eugene McCloskey

ESCEO 2018: Prof. Eugene McCloskey

How should a GP suspect osteoporosis?

Thumbnail

ESCEO 2017: Prof. Serge Ferrari

Management of difficult-to-treat osteoporosis

Thumbnail

ESCEO 2017: Prof. Serge Ferrari

Strategies for patients who discontinue Prolia® and are otherwise naïve

Thumbnail

ESCEO 2017: Prof. Serge Ferrari

Treatment strategies for prior bisphosphonate patients who discontinue Prolia®

thumbnail

ESCEO 2017: Juliet Compston

Call for Action on addressing the crisis in the treatment of osteoporosis

PUBLICATIONS

Discontinuation of Prolia® therapy for osteoporosis: A systematic review and position statement by ECTS
The European Calcified Tissue Society (ECTS) formed a working group to perform a systematic review of existing literature on the effects of Prolia® discontinuation, and provide advice on the management of osteoporosis, a chronic disease that requires long-term treatment. The review highlights the evidence based around Prolia® discontinuation, the need for re-evaluation of patients after 5 years of treatment, and that treatment should not be stopped without considering an alternative anti-resorptive treatment.
Results from the Phase III randomized FREEDOM trial and open-label extension
In the FREEDOM trial and its open-label extension, treatment with Prolia® for up to10 years was associated with consistently low rates of adverse events, a sustained low incidence of fractures and a continued increase in BMD without therapeutic plateau. The authors concluded that long-term treatment with Prolia® is effective, well tolerated and has a favourable benefit-risk profile.
ASBMR: American Society for Bone and Mineral Research; BMD: bone mineral density; ECTS: European Calcified Tissue Society; ESCEO: European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; EULAR: European League Against Rheumatism; FFN: Fragility Fracture Network.

SMPC

The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public